Wockhardt stocks rise; firm says USFDA inspection yields no observations

Shares of drugmaker Wockhardt Ltd rise as much as 2.3 per cent to Rs 460, their highest since April 8. The company says no observations made after US FDA inspects its Bioequivalence centre in Aurangabad, Maharashtra.

Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited, the company had reported. About 425,970 shares change hands in less than half an hour into trading compared with the 30-day average volume of around 1.9 million.

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *